Brolucizumab ophthalmic solution

Phase 3

Alcon Research (ALC)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Neovascular Age-Related Macular Degeneration

Drug Information

Target Indication

Neovascular Age-Related Macular Degeneration

Clinical Trial

NCT02307682

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA2/13/2020

Beovu

Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ALC

Alcon Research

Ophthalmic Goods•North America•NASDAQ

Related Pipeline

Ofloxacin otic solutionPhase 3

Acute Otitis Media

Difluprednate 0.05% ophthalmic emulsionPhase 3

Endogenous Anterior Uveitis

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%Phase 3

Allergic Conjunctivitis

AL-4943A ophthalmic solutionPhase 3

Allergic Conjunctivitis

Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solutionPhase 3

Glaucoma, Open-angle

View full pipeline